Seaport Global Securities started coverage on shares of BeyondSpring (NASDAQ:BYSI) in a research report issued on Tuesday. The brokerage set a “buy” rating on the stock.
Other equities analysts also recently issued research reports about the company. Maxim Group restated a “buy” rating and issued a $52.00 target price on shares of BeyondSpring in a research note on Friday, October 27th. HC Wainwright set a $60.00 target price on BeyondSpring and gave the stock a “buy” rating in a research note on Thursday, October 26th. Finally, Zacks Investment Research downgraded BeyondSpring from a “hold” rating to a “sell” rating in a research note on Monday, November 13th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. BeyondSpring presently has an average rating of “Buy” and an average price target of $54.00.
BeyondSpring (NASDAQ:BYSI) opened at $32.51 on Tuesday. BeyondSpring has a 12 month low of $16.55 and a 12 month high of $48.49.
BeyondSpring (NASDAQ:BYSI) last announced its earnings results on Thursday, November 9th. The company reported ($0.68) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.01. equities analysts anticipate that BeyondSpring will post -4.41 EPS for the current fiscal year.
An institutional investor recently bought a new position in BeyondSpring stock. Tanaka Capital Management Inc. acquired a new stake in BeyondSpring Inc. (NASDAQ:BYSI) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 21,322 shares of the company’s stock, valued at approximately $914,000. BeyondSpring comprises 2.1% of Tanaka Capital Management Inc.’s investment portfolio, making the stock its 16th largest position. Tanaka Capital Management Inc. owned about 0.10% of BeyondSpring as of its most recent SEC filing. 1.22% of the stock is owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION NOTICE: “BeyondSpring (BYSI) Earns Buy Rating from Analysts at Seaport Global Securities” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another website, it was copied illegally and reposted in violation of United States and international copyright laws. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2017/12/05/beyondspring-bysi-earns-buy-rating-from-analysts-at-seaport-global-securities.html.
BeyondSpring Company Profile
BeyondSpring Inc is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC).
Receive News & Ratings for BeyondSpring Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeyondSpring Inc. and related companies with MarketBeat.com's FREE daily email newsletter.